Emerging Therapies for Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been newly developed or extrapolated from their approved use for a different indication. Modes of action and treatment targets have varied as well. Treatments such as vedolizumab and ustekinumab, as well as second-generation corticosteroids have been approved by the US Food and Drug Administration (FDA) for the treatment of IBD. Other agents are currently being developed at various stages of clinical trials including anti-adhesion agents such as etrolizumab and abrilumab, JAK inhibitors such as tofacitinib, and anti-trafficking molecules. Toll-like receptors and phosphatidylcholine are also new promising emerging targets that are being investigated in phase 3 clinical trials. It is projected that many therapies will become available in the coming years if supported by the results of current clinical trials. This will provide IBD patients with a wide array of options and allow physicians to choose the best therapies for each individual patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 1×
“examined the efficacy of FMT in patients with active mild-tomoderate UC [77].”
BackgroundParamsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 1×
“conducted an RCT, introducing two doses of FMT enterally through a nasoduodenal tube [76].”
MethodThe outs and the ins of sphingosine-1-phosphate in immunity
Spiegel, S., & Milstien, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2974 · Cited by 810
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451 · cited 1×
“In a recently published study, 121 moderate-to-severe CD patients ([90% anti-TNF-experienced) were randomized to intravenously receive 200 mg or 600 mg risankizumab or placebo, at weeks 0, 4, and 8 [31].”
BackgroundVermeire, S., Schreiber, S., Petryka, R., Kuehbacher, T., Hebuterne, X., Roblin, X., Klopocka, M., Goldis, A., Wisniewska-Jarosinska, M., Baranovsky, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32537-5 · Cited by 439
Paramsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.049 · Cited by 279
Cited by
Gao, W., Wang, C., Yu, L., Sheng, T., Wu, Z., Wang, X., Zhang, D., Lin, Y., & Gong, Y. (2019) · BioMed Research International · doi:10.1155/2019/6769789 · Cited by 220
Gubatan, J., Levitte, S., Patel, A., Balabanis, T., Wei, M. T., & Sinha, S. R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1920 · Cited by 121
Probiotics in inflammatory bowel disease: Does it work?
Silva, N. O. E., Brito, B. B. D., Silva, F. A. F. D., Santos, M. L. C., & Melo, F. F. D. (2020) · World Journal of Meta-Analysis · doi:10.13105/wjma.v8.i2.54 · Cited by 17
Metadata
- Authors
- Weisshof, R., El Jurdi, K., Zmeter, N., & Rubin, D. T.
- Venue
- Advances in Therapy
- Published
- 2018-10-29
- Volume
- 35
- Issue
- 11
- Pages
- 1746-1762
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2899426586
- Cited by
- 88
- References
- 8
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Therapies for Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1007/s12325-018-0795-9
- The paper
- Weisshof, R., El Jurdi, K., Zmeter, N., & Rubin, D. T. (2018). Emerging Therapies for Inflammatory Bowel Disease. Advances in Therapy. https://doi.org/10.1007/s12325-018-0795-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.